MMED MiniMed Group, Inc.
Executive Summary
Four institutional investors (D.E. Shaw, Citadel, Two Sigma, UBS) significantly increased their MMED positions in Q3 2025, adding a net $9.2M in holdings, while two mega-passive sellers (Morgan Stanley, BofA) trimmed modestly. The cluster is dominated by quantitative funds, suggesting a shared algorithmic or factor-based thesis rather than a fundamental catalyst. Historical calibration data indicates prior reports on MMED have underperformed significantly, and the cluster's net dollar impact is small relative to the $4.1B market cap.
Key Financial Metrics
Institutional Positions
Net institutional flow: $7.6M
▲ Buyers (4)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| D.E. Shaw | DOUBLED | +268.1% | $2.6M | $2.2M |
| Citadel | ADD | +90.1% | $4.0M | $2.8M |
| Two Sigma | DOUBLED | +424.9% | $3.5M | $3.1M |
| Ubs Am, A Distinct Business Un | DOUBLED | +178.3% | $1.4M | $1.1M |
▼ Sellers (2)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Morgan Stanley | TRIM | -28% | $4.5M | -$1.4M |
| BofA | TRIM | -29.5% | $774.0K | -$217.0K |
Actionable Insight
The cluster is dominated by quant funds, which may be responding to price momentum or mean-reversion signals rather than a fundamental catalyst. Given the stock's poor historical performance following prior reports and the small scale of the cluster relative to market cap, this is not a strong directional signal. Monitor for any fundamental catalyst (earnings, product news) that could explain the quant buying.
Key Facts
- 4 buyers added $9.2M in net new holdings; 2 sellers reduced by $1.6M (net cluster inflow ~$7.6M).
- Three of four buyers are quantitative funds (D.E. Shaw, Citadel, Two Sigma) — signal may be factor-driven, not fundamental.
- Morgan Stanley and BofA trimmed ~28-30% of their positions, but their dollar values increased due to stock price appreciation.
- Total institutional buying ($11.4M current holdings) is ~0.3% of MMED's $4.1B market cap — modest scale.
- Historical reports on MMED show a 0% win rate at T+20 with average alpha of -22.9%, suggesting the stock has been a poor performer following prior analyses.
Financial Impact
Net institutional inflow of approximately $7.6M (buyers added $9.2M, sellers reduced $1.6M), representing about 0.2% of market cap.
Risk Factors
- Quantitative buying may be short-term and already unwound given the 45-day 13F reporting lag.
- Historical reports on MMED have shown significant negative alpha at T+20, suggesting poor timing or thesis failure.
- Passive selling by Morgan Stanley and BofA could indicate index rebalancing or risk reduction.
Market Snapshot
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-MMED-2025-Q3 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
9d ago
|
Institutional Cluster
| $15.47 $14.17 | ▼ −8.40% | ▼ −8.84% | — |
|
Jun 3, 2026
17d ago
|
8-K
| $14.26 $14.71 | ▲ +3.16% | ▲ +6.98% | — |
|
May 18, 2026
4w ago
|
8-K
| $10.89 $10.80 | ▼ −0.83% | ▼ −3.12% | — |
|
Apr 27, 2026
7w ago
|
8-K
| $12.92 $11.87 | ▼ −8.13% | ▼ −8.53% | — |
|
Mar 6, 2026
15w ago
|
424B4
| $18.00 $15.96 | ▼ −11.33% | ▼ −9.98% | — |
|
Mar 6, 2026
15w ago
|
EFFECT
| $18.49 $15.76 | ▼ −14.76% | ▼ −13.24% | — |
|
Feb 27, 2026
16w ago
|
S-1/A
| — | awaiting T+5 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access